Best Practice & Research Clinical Endocrinology & Metabolism
Volume 25, Issue 6 , Pages 861-873 , December 2011

Endocrine disorders & female infertility

  • David Unuane, MD (Doctor)

      Affiliations

    • Department of Endocrinology, Universitair Ziekenhuis Brussel, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    • ,
  • Herman Tournaye, MD, PhD (Professor, Doctor)

      Affiliations

    • Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    • ,
  • Brigitte Velkeniers, MD, PhD (Professor, Doctor)

      Affiliations

    • Department of Endocrinology, Universitair Ziekenhuis Brussel, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    • ,
  • Kris Poppe, MD, PhD (Professor, Doctor)

      Affiliations

    • Department of Endocrinology, Universitair Ziekenhuis Brussel, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 4763080; Fax: +32 2 4776428.

References 

  1. Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertility and Sterility. 2008;90:S60
  2. Evers JLH. Female subfertility. Lancet. 2002;360:151–159
  3. Thonneau P, Marchand S, Tallec A, et al. Incidence and main causes of infertility in a resident population of three French regions. Human Reproduction. 1991;6:811–816
  4. Gordon CM. Functional hypothalamic amenorrhea. New England Journal of Medicine. 2010;263:365–371
  5. Caronia LM, Martin C, Welt CK, et al. A genetic basis for functional hypothalamic amenorrhea. New England Journal of Medicine. 2011;364:215–225
  6. Melmed S, Casanueva F, Hoffman A, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96:273–288
  7. Bergh T, Skarin G, Nillius SJ, et al. Pulsatile GnRH therapy — an alternative successful therapy for induction of ovulation in infertile normo- and hyperprolactinaemic amenorrhoeic women with pituitary tumours. Acta Endocrinologica. 1985;110:440–444
  8. Webster J, Pisctelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. New England Journal of Medicine. 1994;33:904–909
  9. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia. A study in 455 patients. Journal of Clinical Endocrinology & Metabolism. 1999;84:2518–2522
  10. Di Sarno A, Landi ML, Marzullo P, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology (Oxford). 2000;53:53–60
  11. Kaltsas GA, Mukherjee JJ, Jenkins PJ, et al. Menstrual irregularity in women with acromegaly. Journal of Clinical Endocrinology & Metabolism. 1999;84:2731–2735
  12. Katznelson L, Kleinberg D, Vance ML, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clinical Endocrinology (Oxford). 2001;54:183–188
  13. Kaltsas GA, Androulakis I, Tziveriotist K, et al. Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clinical Endocrinology (Oxford). 2007;67:917–922
  14. Newell-Price J, Trainer P, Besser M, et al. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocrine Reviews. 1998;19:647–672
  15. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JDC, et al. Menstrual abnormalties in Women with Cushing’s Disease are correlated with Hypercortisolemia rather than raised circulating androgen levels. Journal of Clinical Endocrinology & Metabolism. 1998;83:3083–3088
  16. Iannaccone A, Gabrilove JL, Sohval AR, et al. The ovaries in Cushing’s syndrome. New England Journal of Medicine. 1959;261:775–780
  17. Ga Kaltsas, Korbonits M, Isidori AM, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing’s syndrome?. Clinical Endocrinology (Oxford). 2000;53:493–500
  18. Poppe K, Glinoer D, Van Steirteghem A, et al. Thyroid dysfunction and autoimmunity in infertile women. Thyroid. 2002;12:997–1001
  19. Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ. 2011;9:342;d2616
  20. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocrine Reviews. 2010;31:702–755
  21. Benson RC, Dailey ME. The menstrual pattern in hyperthyroidism and subsequent posttherapy hypothyroidism. Surgery Gynecology & Obstetrics. 1955;100:19–26
  22. Tanaka T, Tamai H, Kuma K, et al. Gonadotropin response to luteinizing hormone releasing hormone in hyperthyroid patients with menstrual disturbances. Metabolism. 1981;30:323–326
  23. Joshi JV, Bhandarkar SD, Chadha M, et al. Menstrual irregularities and lactation failure may precede thyroid dysfunction or goitre. Journal of Postgraduate Medicine. 1993;39:137–141
  24. Krassas GE, Pontikides N, Kaltsas T, et al. Menstrual disturbances in thyrotoxicosis. Clinical Endocrinology (Oxford). 1994;40:641–644
  25. Sturgis SH, Lerman J, Stanbury JB. The menstrual pattern in thyroid disease. Journal of Clinical Endocrinology & Metabolism. 1952;12:846–855
  26. Garsi JP, Schlumberger M, Ricard M, et al. Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer. Journal of Nuclear Medicine. 2008;49:845–852
  27. Ansell JE. The blood in the hypothyroidism. In:  Braverman LE,  Utiger RD editor. Werner and Ingbar’s the thyroid—a fundamental and clinical text. 7th ed. Philadelphia: Lippincott-Raven; 1996;p. 821–825
  28. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clinical Endocrinology (Oxford). 1999;50:655–659
  29. Bohnet HG, Fiedler K, Leidenberger FA. Subclinical hypothyroidism and infertility. Lancet. 1981;2:1278
  30. Gerhard I, Becker T, Eggert-KruseW Klinga K, et al. Thyroid and ovarian function in infertile women. Human Reproduction. 1991;6:338–345
  31. Cramer DW, Sluss PM, Powers RD, et al. Serum prolactin and TSH in an in vitro fertilization population: is there a link between fertilization and thyroid function?. Journal of Assisted Reproduction and Genetics. 2003;20:210–215
  32. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia duet to Steroid 21-Hydroxylase deficiëntie: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2010;95:4133–4160
  33. Nermoen I, Husebye E, Svartberg J, et al. Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway. European Journal of Endocrinology. 2010;163:453–459
  34. Arlt W, Willis D, Wild SH, et al. the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) Health status of Adults with congenital adrenal hyperplasia: a cohort study of 203 patients. Journal of Clinical Endocrinology & Metabolism. 2010;95:5110–5121
  35. Hagenfeldt K, Janson PO, Holmdahl G, et al. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Human Reproduction. 2008;23:1607–1613
  36. Merke DP. Approach to the Adult with congenital adrenal hyperplasia due to 21-Hydroxylase deficiency. Journal of Clinical Endocrinology & Metabolism. 2008;93:653–660
  37. Albert E, Dalaker K, Jorde R, et al. Addison’s disease and pregnancy. Acta Obstetricia et Gynecologica Scandinavica. 1989;68:185–187
  38. Björnsdottir S, Cnattingius S, Brandt L, et al. Addison’s disease in women is a risk factor for an Adverse pregnancy outcome. Journal of Clinical Endocrinology & Metabolism. 2010;95:5249–5257
  39. Martina M, Erichsen MM, Husebye ES, et al. Sexuality and fertility in women with Addison’s disease. Journal of Clinical Endocrinology & Metabolism. 2010;9:4354–4360
  40. Chuang CH, Velott DL, Weisman CS. Exploring knowledge and attitudes related to pregnancy and preconception health in women with chronic medical conditions. Maternal and Child Health Journal. 2010;14:713–719
  41. Erichsen MM, Lovas K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. Journal of Clinical Endocrinology & Metabolism. 2009;94:4882–4890
  42. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Human Reproduction. 2004;19:41–47
  43. Balen AH, Laven JS, Tan SL, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Human Reproduction Update. 2003;9:505–514
  44. March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction. 2010;25:544–551
  45. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. British Medical Journal. 1986;293:355–359
  46. Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. American Journal of Medicine. 2001;111:602–606
  47. Brassard M, AinMelk Y, Baillargeon JP. Basic infertility including polycystic ovary syndrome. Medical Clinics of North America. 2008;92:1163–1192
  48. Legro RS. Pregnancy considerations in women with polycystic ovary syndrome. Clinical Obsterics and Gynecology. 2007;50:295–304
  49. Clark AM, Thornley B, Tomlinson L, et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Human Reproduction. 1998;13:1502–1505
  50. Legro RS, Barnhart HX, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine. 2007;356:551
  51. Moll E, Bossuyt PMM, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. British Medical Journal. 2006;332:1485–1489
  52. Papanikolaou E, Verpoest W, Fatemi H, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertility and Sterility. 2010;95:1174–1177
  53. Al-Sunaidi M, Tulandi T, Holze H, et al. Repeated pregnancies and live births after in-vitro maturation treatment. The combination IVM-ICSI may avoid completely the OHSS risk in PCOS patients. Fertility and Sterility. 2007;87(1212):e9–12
  54. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376:911–921
  55. Donnez J, Dolmans MM, Demylle D, et al. Livebirth afterorthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364:1405–1410
  56. Kuwayama M, Vajta G, Kato O, et al. Highly efficient vitrification method for cryopreservation of humanoocytes. Reproductive Biomedicine Online. 2005;11:300–308

PII: S1521-690X(11)00087-X

doi: 10.1016/j.beem.2011.08.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 25, Issue 6 , Pages 861-873 , December 2011

Article Tools

* Image Usage & Resolution